Cargando…
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
INTRODUCTION: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could help select patients who are likely to benefit from pembrolizumab. METHOD: Patie...
Autores principales: | Ahmadzada, Tamkin, Cooper, Wendy A., Holmes, Mikaela, Mahar, Annabelle, Westman, Helen, Gill, Anthony J., Nordman, Ina, Yip, Po Yee, Pal, Abhijit, Zielinski, Rob, Pavlakis, Nick, Nagrial, Adnan, Daneshvar, Dariush, Brungs, Daniel, Karikios, Deme, Aleksova, Vesna, Burn, Juliet, Asher, Rebecca, Grau, Georges E., Hosseini-Beheshti, Elham, Reid, Glen, Clarke, Stephen, Kao, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474198/ https://www.ncbi.nlm.nih.gov/pubmed/34589956 http://dx.doi.org/10.1016/j.jtocrr.2020.100075 |
Ejemplares similares
-
Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential
por: Ahmadzada, Tamkin, et al.
Publicado: (2023) -
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
por: Ahmadzada, Tamkin, et al.
Publicado: (2018) -
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020) -
Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis
por: Hayes, Aimee R., et al.
Publicado: (2018) -
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
por: Bickel, Angelika, et al.
Publicado: (2016)